⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Shionogi & Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Shionogi & Co., Ltd.
↗Osaka, Japan
Shionogi is a Japanese pharmaceutical company with roots dating back to 1878, now a global innovator in drug discovery and development. The company specializes in developing novel therapeutics across infectious diseases (core competence with 60+ years of antimicrobial expertise), oncology/immuno-oncology, rare diseases, and CNS/pain. Shionogi is publicly traded on the Tokyo Stock Exchange (ticker: 4507) and maintains operations across Japan, North America, Europe, and Asia. The company is advancing 11 antimicrobial projects (9 bacterial, 2 fungal) with 8 targeting critical/urgent pathogens, plus clinical programs in stroke, rare disease, and oncology.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharma - Anti-Infectives, Rare Disease, Oncology
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$2.93B
Founded:1878
Ownership:public
Status:operating
FUNDING
Stage:N/A - Publicly traded since 1919
STOCK
Exchange:Tokyo Stock Exchange / OTC (ADRs)
Ticker:4507.T / SGIOY / SGIOF
Market Cap:$18.6B
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Commercial
Lead Drug Stage:Phase 2/Phase 3 programs advancing; multiple candidates in development
Modalities:Small molecule, Monoclonal antibodies (mAbs), Long-acting injectables, Oral antivirals, Substrate reduction therapy
Active Trials:12
Trial Phases:Phase 1: 2 | Phase 2: 5 | Phase 3: 3 | Phase 4: 2
FDA Approvals:8
EMA Approvals:4
CORPORATE STRUCTURE
Subsidiaries:Shionogi Inc. (USA), ViiV Healthcare (21.7% stake as of Jan 2026), Shionogi Europe, Shionogi China Co., Ltd.
Key Partnerships:ViiV Healthcare - HIV treatments (Apretude, Dovato, Triumeq, Tivicay, Cabenuva); Shionogi increased stake to 21.7% in January 2026, Qpex Biopharma - antimicrobial R&D expansion in US, Maze Therapeutics - S-606001 for late-onset Pompe disease, AstraZeneca - Crestor licensing and royalties, Tanabe Pharma - RADICAVA acquisition (planned)
COMPETITION
Position:Leader in anti-infectives; Challenger in oncology and rare diseases
Competitors:Pfizer, Roche, Novartis, Eli Lilly, Bayer, Astellas Pharma, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical +6 more
LEADERSHIP
Key Executives:
Isao Teshirogi - Representative Director, President, CEO
Keiichi Ando - Chairperson of Board
Takuko Sawada - Vice Chairman, Director
Nathan McCutcheon - President & CEO, Shionogi Inc. (USA)
Tadashi Hara - Executive Vice President, Chief Global Operations Officer (USA)
Joseph Spagnardi - Executive Vice President, Legal and Compliance
Gianine Esposito - Senior Vice President, Chief Human Resources Officer
Margaret Borys - Senior Vice President, Chief Commercial Officer
Huw Tippett - Chief Executive Officer, Shionogi Europe
Board Members:Keiichi Ando - Chairperson, Isao Teshirogi - President/CEO, Takuko Sawada - Vice Chairman, Junko Goto - Chairperson of Audit and Supervisory Committee, 7 Outside Independent Directors (including women and international representation), Total: 11 Directors (6 non-ASC, 5 ASC members)
LINKS
Website:shionogi.com
LinkedIn:LinkedIn Profile
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Shionogi & Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.